The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
暂无分享,去创建一个
J. Wallach | J. Ross | H. Naci
[1] Sania Amr,et al. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014 , 2018, Clinical pharmacology and therapeutics.
[2] R. Califf. Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full , 2018, Clinical trials.
[3] J. Wallach,et al. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements , 2018, Clinical trials.
[4] R. Schilsky. Access versus evidence: The regulators’ dilemma , 2018, Clinical trials.
[5] J. Woodcock. Expediting drug development for serious illness: Trade-offs between patient access and certainty , 2018, Clinical trials.
[6] L. Howie,et al. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review , 2018, JAMA oncology.
[7] J. Wallach,et al. Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts. , 2018, JAMA.
[8] Lisa M. Schwartz,et al. The Fate of FDA Postapproval Studies. , 2017, The New England journal of medicine.
[9] A. Kesselheim,et al. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study , 2017, British Medical Journal.
[10] A. Kesselheim,et al. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration , 2017, JAMA.
[11] J. Ioannidis,et al. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval , 2017, The Milbank quarterly.
[12] Harlan M. Krumholz,et al. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 , 2017, JAMA.
[13] H. Krumholz,et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review , 2017, British Medical Journal.
[14] G. D. Dal Pan,et al. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals , 2017, Drug Safety.
[15] M. Drummond,et al. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] Petra Kaufmann,et al. Transforming Evidence Generation to Support Health and Health Care Decisions. , 2016, The New England journal of medicine.
[17] K. V. Chary. Expedited drug review process: Fast, but flawed , 2016, Journal of pharmacology & pharmacotherapeutics.
[18] Jonathan J. Darrow,et al. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study , 2015, BMJ : British Medical Journal.
[19] Harlan M. Krumholz,et al. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. , 2014, JAMA.
[20] G. Alexander,et al. The Food and Drug Administration Amendments Act and postmarketing commitments. , 2013, JAMA.
[21] B. Psaty,et al. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. , 2012, JAMA.